Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 6469

Next Previous
Drug Profile

MEDI 6469

Alternative Names: Anti-OX40 monoclonal antibody; MEDI-6469; Murine-anti-OX40-MAb

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AgonOx; Providence Cancer Center
  • Developer AstraZeneca; Providence Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Diffuse large B cell lymphoma; Head and neck cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 21 Dec 2023 Providence Cancer Center completes phase I trials in Head and neck cancer (First-line therapy, Neoadjuvant therapy, Late-stage disease) in USA (IV) (NCT02274155)
  • 14 Feb 2022 Providence Health Services and MedImmune terminates a phase I/II trial in Colorectal cancer (Metastatic disease) in USA (IV) (NCT02559024)
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Colorectal-cancer(Metastatic disease) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top